Alexander A Vinks

List of Publications by Citations

154 papers	3,932 citations	31 h-index	58 g-index
175 ext. papers	4,991 ext. citations	4.4 avg, IF	5.45 L-index

#	Paper	IF	Citations
154	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infectious Diseases, The*, **2014**, 14, 498-509	25.5	534
153	Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. *Pediatrics*, **2016**, 137, e20153257	7.4	399
152	Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 518-25	4.7	169
151	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Therapeutic Drug Monitoring*, **2019**, 41, 261-307	3.2	163
150	Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. *Clinical Transplantation*, **2008**, 22, 281-91	3.8	130
149	Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy For Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 307-315	4.7	95
148	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. *Neuro-Oncology*, **2015**, 17, 596-603	1	91
147	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. *Transplantation Reviews*, **2011**, 25, 47-57	3.3	89
146	1543. Ceftaroline Model-based Dose Individualization in an Infant with Kidney Disease and Mediastinitis. *Open Forum Infectious Diseases*, **2019**, 6, S563-S563	1	78
145	OCT1 genetic variants influence the pharmacokinetics of morphine in children. *Pharmacogenomics*, **2013**, 14, 1141-51	2.6	73
144	Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. *Pediatric Blood and Cancer*, **2014**, 61, 982-6	3	65
143	Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. *Oncologist*, **2018**, 23, 52-61	5.7	63
142	ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. *Pharmacogenomics*, **2014**, 15, 1297-309	2.6	58
141	Morphine clearance in children: does race or genetics matter?. *Journal of Opioid Management*, **2012**, 8, 217-26	0.8	52
140	Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3449-51	5.9	51
139	Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. *Clinical Pharmacokinetics*, **2012**, 51, 543-551	6.2	50
138	Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. *Journal of Clinical Pharmacology* , **2011**, 51, 309-20	2.9	50

137	Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. *International Journal of Antimicrobial Agents*, **2014**, 43, 223-30	14.3	49
136	Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. *Clinical Drug Investigation*, **2013**, 33, 523-34	3.2	49
135	Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 541-7	5.9	48
134	Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. *Pediatric Blood and Cancer*, **2017**, 64, e26470	3	46
133	Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. *American Journal of Transplantation*, **2019**, 19, 1410-1420	8.7	44
132	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. *Clinical Pharmacokinetics*, **2011**, 50, 1-24	6.2	41
131	Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. *American Journal of Transplantation*, **2019**, 19, 2944-2948	8.7	40
130	Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3049-55	5.9	40
129	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. *American Journal of Hematology*, **2019**, 94, 871-879	7.1	35
128	Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. *Journal of Pediatrics*, **2014**, 165, 440-6	3.6	35
127	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. *Therapeutic Drug Monitoring*, **2015**, 37, 718-24	3.2	35
126	Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. *Journal of Pediatrics*, **2015**, 167, 1214-20.e3	3.6	34
125	The application of population pharmacokinetic modeling to individualized antibiotic therapy. *International Journal of Antimicrobial Agents*, **2002**, 19, 313-22	14.3	33
124	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. *British Journal of Clinical Pharmacology*, **2012**, 73, 727-40	3.8	32
123	Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 49-52	6.1	31
122	CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. *Pharmacogenomics*, **2017**, 18, 337-348	2.6	28
121	OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. *Pharmacogenomics*, **2017**, 18, 621-629	2.6	28
120	Recommendations for the design of therapeutic trials for neonatal seizures. *Pediatric Research*, **2019**, 85, 943-954	3.2	28

119	Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 482-6	4.7	28
118	Evaluation of propofol anesthesia in morbidly obese children and adolescents. *BMC Anesthesiology*, **2013**, 13, 8	2.4	28
117	Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 761-768	6.1	27
116	Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. *British Journal of Clinical Pharmacology*, **2016**, 81, 742-52	3.8	26
115	Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. *European Journal of Pharmaceutical Sciences*, **2017**, 109S, S124-S131	5.1	25
114	Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 4568-4577	5.6	24
113	PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 464-473	4.5	23
112	Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. *Therapeutic Drug Monitoring*, **2013**, 35, 332-7	3.2	23
111	Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. *Paediatric Anaesthesia*, **2015**, 25, 911-923	1.8	22
110	ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. *Pharmacogenomics Journal*, **2017**, 17, 162-169	3.5	21
109	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. *PLoS Medicine*, **2017**, 14, e1002428	11.6	21
108	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. *Clinical Transplantation*, **2017**, 31, e12975	3.8	20
107	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. *Neuro-Oncology*, **2020**, 22, 1527-1535	1	20
106	The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. *British Journal of Clinical Pharmacology*, **2015**, 80, 1438-46	3.8	20
105	Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2020**, 26, 429-439	4.5	20
104	Measuring Medication Adherence in Pediatric Cancer: An Approach to Validation. *Journal of Pediatric Psychology*, **2017**, 42, 232-244	3.2	19
103	Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children. *Drug Metabolism and Disposition*, **2017**, 45, 23-26	4	18
102	Development and Implementation of Electronic Health Record-Integrated Model-Informed Clinical Decision Support Tools for the Precision Dosing of Drugs. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 129-135	6.1	18

101	Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 635-641	4.7	17
100	Learning Health Systems as Facilitators of Precision Medicine. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 359-367	6.1	16
99	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. *Clinical Cancer Research*, **2015**, 21, 1558-65	12.9	16
98	Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. *Journal of Parenteral and Enteral Nutrition*, **2016**, 40, 860-8	4.2	16
97	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. *Journal of Clinical Oncology*, **2021**, 39, 797-806	2.2	16
96	Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations. *Journal of Clinical Pharmacology*, **2016**, 56, 291-7	2.9	16
95	A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures. *Annals of Neurology*, **2021**, 89, 327-340	9.4	16
94	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. *Journal of Thrombosis and Thrombolysis*, **2017**, 44, 38-47	5.1	15
93	A Theoretical Physiologically-Based Pharmacokinetic Approach to Ascertain Covariates Explaining the Large Interpatient Variability in Tacrolimus Disposition. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 273-284	4.5	15
92	Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 186-194	6.1	15
91	A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2220-2225	4.7	14
90	MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 635-643	6.1	13
89	Validation of a pediatric population pharmacokinetic model for vancomycin. *Therapeutic Drug Monitoring*, **2015**, 37, 413-6	3.2	13
88	Propofol clearance in morbidly obese children and adolescents: influence of age and body size. *Clinical Pharmacokinetics*, **2012**, 51, 543-51	6.2	13
87	Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. *PLoS ONE*, **2016**, 11, e0146563	3.7	13
86	Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib. *Pediatric Blood and Cancer*, **2019**, 66, e27618	3	12
85	Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs. *Pediatric Transplantation*, **2017**, 21, e13033	1.8	12
84	Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 254-260	5.1	12

83	Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. *Journal of Cardiovascular Pharmacology*, **2016**, 67, 175-81	3.1	12
82	Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1639-1647	6.1	12
81	Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. *British Journal of Clinical Pharmacology*, **2017**, 83, 1097-1107	3.8	11
80	Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac Surgery. *Therapeutic Drug Monitoring*, **2018**, 40, 186-194	3.2	11
79	Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies. *Pediatric Clinics of North America*, **2017**, 64, 1417-1438	3.6	11
78	Retrospective Evaluation of Milrinone Pharmacokinetics in Children With Kidney Injury. *Therapeutic Drug Monitoring*, **2015**, 37, 792-6	3.2	11
77	Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. *Journal of Visualized Experiments*, **2015**, e52424	1.6	11
76	Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. *Journal of Clinical Pharmacology*, **2019**, 59, 168-176	2.9	11
75	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. *Neuro-Oncology*, **2018**, 20, i143-i143	1	11
74	Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations. *CPT: Pharmacometrics and Systems Pharmacology*, **2018**, 7, 237-250	4.5	10
73	Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. *British Journal of Clinical Pharmacology*, **2014**, 78, 1102-12	3.8	10
72	Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. *Therapeutic Drug Monitoring*, **2015**, 37, 395-9	3.2	9
71	Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery. *Clinical Pharmacokinetics*, **2019**, 58, 793-803	6.2	9
70	Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children. *Pharmacogenomics*, **2017**, 18, 143-156	2.6	8
69	Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. *Clinical Pharmacokinetics*, **2018**, 57, 625-636	6.2	8
68	Intermediate term thrombotic risk in contemporary total cavo-pulmonary connection for single ventricle circulations. *Journal of Thrombosis and Thrombolysis*, **2017**, 44, 275-280	5.1	8
67	Obesity and overweight as CAE comorbidities and differential drug response modifiers. *Neurology*, **2016**, 86, 1613-21	6.5	8
66	A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1829-1835	4.7	8

65	Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. *Clinical Pharmacokinetics*, **2017**, 56, 1207-1217	6.2	7
64	Pharmacokinetics and Safety of Single-Dose Inhaled Loxapine in Children and Adolescents. *Journal of Clinical Pharmacology*, **2017**, 57, 1244-1257	2.9	6
63	Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. *European Journal of Pharmaceutical Sciences*, **2019**, 128, 209-214	5.1	6
62	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. *British Journal of Clinical Pharmacology*, **2020**,	3.8	6
61	Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. *Trials*, **2020**, 21, 983	2.8	6
60	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. *Pediatric Blood and Cancer*, **2021**, 68, e28787	3	6
59	Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. *Journal of Clinical Pharmacology*, **2021**, 61, 857-870	2.9	6
58	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. *Clinical Pharmacokinetics*, **2017**, 56, 107-125	6.2	5
57	Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients. *Journal of Clinical Pharmacology*, **2020**, 60, 992-998	2.9	5
56	A Phase I Trial Of Zileuton In Sickle Cell Disease. *Blood*, **2013**, 122, 993-993	2.2	5
55	Methodologic Progress Note: Opportunistic Sampling for Pharmacology Studies in Hospitalized Children. *Journal of Hospital Medicine*, **2021**, 16, 35-37	2.7	5
54	Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. *Journal of Clinical Pharmacology*, **2020**, 60, 453-465	2.9	5
53	Pharmacokinetics and pharmacogenomics of Ɓlactam-induced neutropenia. *Pharmacogenomics*, **2016**, 17, 547-59	2.6	5
52	Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. *Expert Opinion on Drug Metabolism and Toxicology*, **2021**, 17, 87-103	5.5	5
51	Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2416-2421	4.7	4
50	Opportunities for model-based precision dosing in the treatment of sickle cell anemia. *Blood Cells, Molecules, and Diseases*, **2017**, 67, 143-147	2.1	4
49	Model-Informed Bayesian Estimation Improves the Prediction of Morphine Exposure in Neonates and Infants. *Therapeutic Drug Monitoring*, **2020**, 42, 778-786	3.2	4
48	Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. *Clinical Pharmacokinetics*, **2021**, 60, 249-259	6.2	4

47	Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial. *Intensive Care Medicine*, **2018**, 44, 2006-2008	14.5	4
46	Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders. *Molecular Genetics and Metabolism*, **2018**, 125, 251-257	3.7	4
45	Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. *British Journal of Clinical Pharmacology*, **2021**,	3.8	4
44	Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). *Journal of Pediatrics*, **2020**, 222, 236-239	3.6	3
43	Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1651-1658	5.1	3
42	Hydroxyurea Exposure in Lactation Pharmacokinetics Study (HELPS). *Blood*, **2018**, 132, 3677-3677	2.2	3
41	Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases. *Blood*, **2016**, 128, 2203-2203	2.2	3
40	Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. *Cardiology Research*, **2020**, 11, 294-304	1.8	3
39	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. *Frontiers in Pharmacology*, **2020**, 11, 605060	5.6	3
38	Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients. *British Journal of Clinical Pharmacology*, **2020**, 86, 933-943	3.8	3
37	Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets. *Pharmacotherapy*, **2020**, 40, 1061-1068	5.8	3
36	Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children. *Pediatric Infectious Disease Journal*, **2019**, 38, 1224-1227	3.4	3
35	Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. *Pediatric Blood and Cancer*, **2019**, 66, e27425	3	3
34	Sirolimus Treatment in Sturge-Weber Syndrome. *Pediatric Neurology*, **2021**, 115, 29-40	2.9	3
33	Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of Lactam Antibiotics in Critically Ill Children. *Journal of Clinical Pharmacology*, **2021**, 61, 565-573	2.9	3
32	Test Dose Pharmacokinetics to Predict Melphalan Dosing in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT) with Organ Impairment?. *Biology of Blood and Marrow Transplantation*, **2017**, 23, S228	4.7	2
31	Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. *Pharmacotherapy*, **2019**, 39, 564-575	5.8	2
30	Pediatric Phase II Study of Maraviroc for Acute Graft Versus Host Disease Prophylaxis. *Biology of Blood and Marrow Transplantation*, **2019**, 25, S251-S252	4.7	2

29	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. *Blood*, **2016**, 128, 3652-3652	2.2	2
28	Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	2
27	A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome. *Pharmacology & Therapeutics*, **2021**, 108045	13.9	2
26	Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted to Observed Morphine Concentration in Critically Ill Neonates. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 319-320	6.1	2
25	Hydromorphone population pharmacokinetics in pediatric surgical patients. *Paediatric Anaesthesia*, **2020**, 30, 1091-1101	1.8	2
24	Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. *Cardiovascular Drugs and Therapy*, **2021**, 1	3.9	2
23	Status Toward the Implementation of Precision Dosing in Children. *Journal of Clinical Pharmacology* , **2021**, 61 Suppl 1, S36-S51	2.9	2
22	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. *British Journal of Haematology*, **2021**, 194, 617-625	4.5	2
21	Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. *journal of applied laboratory medicine, The*, **2021**, 6, 625-636	2	2
20	A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. *Bone Marrow Transplantation*, **2021**, 56, 3029-3031	4.4	2
19	Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. *British Journal of Clinical Pharmacology*, **2018**, 84, 1410-1412	3.8	1
18	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. *Blood*, **2018**, 132, 507-507	2.2	1
17	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. *Blood*, **2019**, 134, 3830-3830	2.2	1
16	Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger. *Therapeutic Drug Monitoring*, **2021**, 43, 719-727	3.2	1
15	Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS-Modified Electrodes and Chemometrics. *Biomedicines*, **2020**, 9,	4.8	1
14	Toward pharmacogenetic SLCO1B1-guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model. *Clinical and Translational Science*, **2021**, 14, 2267-2277	4.9	1
13	Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. *British Journal of Clinical Pharmacology*, **2021**,	3.8	1
12	Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. *Journal of Clinical Pharmacology*, **2021**, 61, 547-554	2.9	1

11	Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 2923-2931	5.1	1
10	Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.. *Alimentary Pharmacology and Therapeutics*, **2021**,	6.1	1
9	Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment. *Antimicrobial Agents and Chemotherapy*, **2021**, AAC0142721	5.9	0
8	Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. *Journal of Clinical Pharmacology*, **2021**, 61 Suppl 1, S52-S59	2.9	0
7	Hydroxyurea improves cerebral oxygen saturation in children with sickle cell anemia. *American Journal of Hematology*, **2021**, 96, 538-544	7.1	0
6	Therapeutisches Drug Monitoring in der Pädiatrie / Therapeutic drug management in pediatric patients. *Laboratoriums Medizin*, **2007**, 31, 24-37		
5	Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study. *Blood*, **2021**, 138, 980-980	2.2	
4	Characterizing important determinants of Tacrolimus pharmacokinetic variability in renal transplant patients: PBPK modeling approach using genotyped patients information. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, OR22-3	0	
3	Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption. *Blood*, **2019**, 134, 4893-4893	2.2	
2	Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. *Blood*, **2015**, 126, 982-982	2.2	
1	Roger W. Jelliffe, MD, FCP, FAAPS: A World Leader in Population Pharmacokinetic and Pharmacodynamic Modeling and Model-Based Target Controlled Individualized Dosing. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 22-24	6.1	